AstraZeneca Announces Non-Vaccine COVID Prevention Therapy with 77% Efficacy

August 20, 2021

AstraZeneca just announced that they’ve developed a non-vaccine therapy, called AZD7442, which reduces the risk of developing COVID-19. This combination of two long-acting antibodies* (LAAB) is administered intramuscularly and was found to cut the risk of developing symptomatic COVID-19 by 77% compared to placebo in the clinical trial.

The trial included 5,197 unvaccinated participants and more than 75% had comorbidities, including those with immunosuppressive disease or taking immunosuppressive medications, diabetes, severe obesity or cardiac disease, chronic obstructive pulmonary disease, chronic kidney, and chronic liver disease.

* AZD7442 is a combination of two LAABs – tixagevimab (AZD8895) and cilgavimab (AZD1061) – derived from B-cells donated by recovering patients after SARS-CoV-2 virus infection.





Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.